OptimizeRx Corporation (OPRX)

OptimizeRx Corp. (OPRX) stock has experienced significant fluctuations in the past six months. Between November 19, 2024, and November 18, 2025, the share price increased by 246.08%. Over the last 12 months, the stock's price increased by 208.42%, with a year-to-date return of 216.67%. However, in the past month (leading up to November 26, 2025), the stock decreased by 29.01%. Key events impacting the stock price include earnings conference calls, participation in investor conferences, and the acquisition of Healthy Offers, Inc.

The pharmaceutical brand marketing industry, in which OptimizeRx operates, generally experiences seasonal trends. Pharmaceutical companies typically allocate the largest portion of their brand marketing budgets to the fourth quarter of the calendar year, resulting in lower activity levels and lower revenue in the first quarter, with gradual increases in the subsequent quarters.

OptimizeRx Corp. is a digital healthcare technology company focused on improving patient outcomes and medication adherence by delivering information, educational resources, and financial support tools to healthcare providers. Its platform includes the Dynamic Audience Activation Platform (DAAP), Micro-Neighborhood Targeting (MNT), Profiler, Banner Messages, Media Execution Solutions, Pharmacy Alerts, and Financial Messaging Solutions. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

OptimizeRx Corp. primarily focuses on the U.S. healthcare market, with 94% of its revenue derived from North America, 5% from Europe, and 1% from other regions. The company's network reaches over 70% of U.S. healthcare providers.

OptimizeRx has demonstrated strong revenue growth, driven by increased adoption of its digital health solutions and strategic partnerships. The company has shown profitability improvement with significant year-over-year improvement in Adjusted EBITDA and a narrowing GAAP/non-GAAP net loss. Management has also raised full-year revenue and EBITDA guidance. While no specific negative events were detailed, the competitive nature of the digital pharma marketing landscape is an implied challenge.

OptimizeRx Corporation has a mixed ownership structure, with institutional investors holding a 68% stake, individual investors holding a 19% stake, and insiders holding a significant stake. Major institutional owners include Whetstone Capital Advisors, LLC, BlackRock, Inc., and Vanguard Group Inc., with First Light Asset Management, LLC being the largest shareholder.